Status:

COMPLETED

Stenting and Angioplasty With Protection in Patients at High Risk for Endarterectomy (SAPPHIRE)

Lead Sponsor:

Cordis US Corp.

Conditions:

Carotid Artery Disease

Eligibility:

All Genders

18-80 years

Phase:

PHASE3

Brief Summary

The primary objective of this study is to compare the safety and effectiveness of the Cordis Nitinol Carotid Stent and Delivery Systems (5.5 F and 7 F) with the ANGIOGUARD XP distal protective device ...

Eligibility Criteria

Inclusion

  • The patient must be \> 18 years of age.
  • The patient has a 50% stenosis (as determined by ultrasound or angiogram) of the common or internal carotid artery and is clinically symptomatic; i.e., within the previous 180 days has experienced symptoms in the ipsilateral carotid artery distribution, defined as:
  • one or more TIAs, characterized by distinct focal neurologic dysfunction or monocular blindness with clearing of signs and symptoms within 24 hours, or
  • one or more completed strokes (as defined by this protocol) with persistence of symptoms or signs for more than 24 hours (the most recent event is used as the qualifying event), except as excluded below, with stenosis \>50%, (as determined by ultrasound or angiogram) of the common or internal carotid artery, OR The patient must have a \>80% diameter stenosis (as determined by ultrasound or angiogram) of the internal or common carotid artery without neurological symptoms.
  • To be entered into the study, the patient must have one or more of the following conditions:
  • congestive heart failure (class III/IV) and/or known severe left ventricular dysfunction LVEF \< 30%
  • open heart surgery within six weeks
  • recent MI (\>24 hours and \<4 weeks)
  • unstable angina (CCS class III/IV)
  • synchronous severe cardiac and carotid disease requiring open heart surgery and carotid revascularization
  • Age greater than 80 years as a single risk factor.

Exclusion

  • The patient is experiencing an acute ischemic neurologic stroke or has experienced a stroke within the past 48 hours.
  • The patient has an intracranial mass lesion (i.e., abscess, tumor, or infection).
  • The reference segment diameter (distal common carotid and internal carotid artery segment cephalic to the lesion) is less than 4mm or greater than 9mm by quantitative analysis. See Instructions For Use, for proper stent sizing. The exception to this would be with a lesion having \>95% stenosis where the true diameter of the distal vessel can not be determined such as the case with a string sign or distal vessel collapse. In this case the judgment of the interventionalist will prevail with the intention not to oversize the stent to the distal vessel by more than 2mm.
  • The patient has known peripheral vascular, supra-aortic or internal carotid artery tortuosity which preclude the use of catheter-based techniques if so randomized.
  • The patient has any intracranial aneurysm (\> 9 mm).

Key Trial Info

Start Date :

August 1 2000

Trial Type :

INTERVENTIONAL

End Date :

August 1 2005

Estimated Enrollment :

1300 Patients enrolled

Trial Details

Trial ID

NCT00231270

Start Date

August 1 2000

End Date

August 1 2005

Last Update

April 24 2008

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.